Stock Events

Stock Events

Tonix Pharmaceuticals 

0
585
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 9Expected
Q1 2026
Q2 2026
Next
-2.49
-2.36
-2.24
-2.11
Expected EPS
-2.143480283
Actual EPS
N/A

Financials

-941.98%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
11.34MRevenue
-106.79MNet Income

Analyst Ratings

$16.69Average Price Target
The highest estimate is ⁦19.73⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TPMP.MU. It's not an investment recommendation.
Apple
69
AAPL
NVIDIA
68
NVDA
Microsoft
58
MSFT
Tesla
58
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.66B
Novavax is involved in the development of vaccines and therapeutics for infectious diseases, directly competing with Tonix's focus on immunology and infectious diseases.
Moderna
MRNA
Mkt Cap88.52B
Moderna is a leader in mRNA technology for vaccines, competing in the infectious disease space where Tonix Pharmaceuticals also operates.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech competes in the development of vaccines and immunotherapies, overlapping with Tonix's focus areas.
Pfizer
PFE
Mkt Cap173.95B
Pfizer develops vaccines and therapeutics for a wide range of diseases, including those in Tonix's research areas, making it a direct competitor.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments and vaccines for infectious diseases, competing with Tonix.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences focuses on antiviral drugs for infectious diseases, directly competing with Tonix's development of treatments for similar conditions.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in the development of treatments for infectious diseases, making it a competitor to Tonix.
Sanofi
SNY
Mkt Cap106.24B
Sanofi works on vaccines and treatments for infectious diseases, directly competing with Tonix Pharmaceuticals in several areas.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca develops vaccines and treatments for various diseases, including infectious diseases, competing with Tonix's portfolio.

About

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Show More
CEO
Seth Lederman
Employees
142
Country
United States
ISIN
US8902605083

Listings

XNAS
US
TNXP
STU
DE
TPMN.STU
STU
DE
TPM0.STU
MU
DE
TPM0.MU

0 Comments

Share your thoughts

FAQs

What is Tonix Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Tonix Pharmaceuticals stocks are traded under the ticker TPMP.MU.
When is the next Tonix Pharmaceuticals earnings date?▼
Tonix Pharmaceuticals is going to release the next earnings report on November 9, 2026.
What were Tonix Pharmaceuticals earnings last quarter?▼
TPMP.MU earnings for the last quarter are -2.11 EUR per share, whereas the estimation was -2.29 EUR resulting in a +7.66% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Tonix Pharmaceuticals revenue for the last year?▼
Tonix Pharmaceuticals revenue for the last year amounts to 11.34M EUR.
What is Tonix Pharmaceuticals net income for the last year?▼
TPMP.MU net income for the last year is -106.79M EUR.
How many employees does Tonix Pharmaceuticals have?▼
As of November 7, 2026, the company has 142 employees.
In which sector is Tonix Pharmaceuticals located?▼
Tonix Pharmaceuticals operates in the Health & Wellness sector.
When did Tonix Pharmaceuticals complete a stock split?▼
The last stock split for Tonix Pharmaceuticals was on November 1, 2019 with a ratio of 1:10.
Where is Tonix Pharmaceuticals headquartered?▼
Tonix Pharmaceuticals is headquartered in BERKELEY HEIGHTS, United States.